Literature DB >> 3069394

Role of advanced glycosylation products in complications of diabetes.

A Cerami1, H Vlassara, M Brownlee.   

Abstract

Glucose and other reducing sugars can react with proteins and nucleic acids, without the aid of enzymes, to form stable covalent adduct. These reactions, although studied by food chemists, have recently been found to occur in vivo. This has led to studies on the accumulation of these advanced glycosylation end products (AGE) and the role it plays in the aging of long-lived proteins and nucleic acids. In contrast to the Amadori product, which is in equilibrium with glucose, AGE is irreversibly attached to the proteins. The AGE moieties are brown, fluorescent chromophores that can cross-link proteins. We have identified and characterized two specific AGE glucose-derived cross-links in proteins 2-furoyl-4(5)-(2-furanyl)-1H-imidazole (FFI) and 1-alkyl-2-formyl-3,4-diglycosylpyrrole (AFGP). By use of a radioimmunoassay for FFI identification, it has been possible to demonstrate the presence of FFI in situ in proteins that had been exposed to glucose in vitro and in vivo. Recently, we found that reducing sugars react with amino groups on DNA nucleotides in a manner analogous to the nonenzymatic glycosylation of amino groups on proteins. The AGE-DNA formed in this manner has spectral and fluorescent properties similar to those of AGE-proteins. We have observed that formation of AGE on DNA decreases the ability of the single-stranded virus f1 to transfect Escherichia coli. When the plasmid pBR322 containing ampicillin- and tetracycline-resistant genes is incubated with reducing sugars, specific mutations are observed. These mutations have been found to be caused by insertions and deletions of the DNA. Further studies are needed for measuring the amounts of AGE-DNA and proteins linked to DNA by AGE. Potential mechanisms for repair of AGE-DNA also needs to be explored further.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3069394

Source DB:  PubMed          Journal:  Diabetes Care        ISSN: 0149-5992            Impact factor:   19.112


  16 in total

1.  [Neurodegeneration and neuroprotection].

Authors:  K-G Schmidt
Journal:  Ophthalmologe       Date:  2004-11       Impact factor: 1.059

Review 2.  Calcium-binding protein S100P and cancer: mechanisms and clinical relevance.

Authors:  Hongfei Jiang; Hang Hu; Xiaomei Tong; Qiuhong Jiang; Haiyan Zhu; Songying Zhang
Journal:  J Cancer Res Clin Oncol       Date:  2011-09-24       Impact factor: 4.553

3.  Amadori adducts activate nuclear factor-kappaB-related proinflammatory genes in cultured human peritoneal mesothelial cells.

Authors:  Julián Nevado; Concepción Peiró; Susana Vallejo; Mariam El-Assar; Nuria Lafuente; Nuria Matesanz; Verónica Azcutia; Elena Cercas; Carlos F Sánchez-Ferrer; Leocadio Rodríguez-Mañas
Journal:  Br J Pharmacol       Date:  2005-09       Impact factor: 8.739

Review 4.  Prospects for the use of antioxidant therapies.

Authors:  S R Maxwell
Journal:  Drugs       Date:  1995-03       Impact factor: 9.546

5.  Different regional changes of fluorescence spectra of clear human lenses and nuclear cataracts.

Authors:  H Pau; J Degen; H H Schmidtke
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1993-11       Impact factor: 3.117

6.  The effect of ascorbic acid on protein glycation in streptozotocin-diabetic rats.

Authors:  M Gembal; J Druzyńska; M Kowalczyk; E Przepiera; M Cybal; W Arendarczyk; C Wójcikowski
Journal:  Diabetologia       Date:  1994-07       Impact factor: 10.122

7.  Pro-inflammatory effects of early non-enzymatic glycated proteins in human mesothelial cells vary with cell donor's age.

Authors:  L Rodríguez-Mañas; C Sánchez-Rodríguez; S Vallejo; M El-Assar; C Peiró; V Azcutia; N Matesanz; C F Sánchez-Ferrer; J Nevado
Journal:  Br J Pharmacol       Date:  2006-10-30       Impact factor: 8.739

8.  Glycosylated human oxyhaemoglobin activates nuclear factor-kappaB and activator protein-1 in cultured human aortic smooth muscle.

Authors:  Concepcion Peiro; Nuria Matesanz; Julian Nevado; Nuria Lafuente; Elena Cercas; Veronica Azcutia; Susana Vallejo; Leocadio Rodriguez-Manas; Carlos F Sanchez-Ferrer
Journal:  Br J Pharmacol       Date:  2003-09-22       Impact factor: 8.739

9.  Sustained effect of intensive treatment of type 1 diabetes mellitus on development and progression of diabetic nephropathy: the Epidemiology of Diabetes Interventions and Complications (EDIC) study.

Authors: 
Journal:  JAMA       Date:  2003-10-22       Impact factor: 56.272

Review 10.  Prevention of complications in non-insulin-dependent diabetes mellitus (NIDDM).

Authors:  B H Wolffenbuttel; T W van Haeften
Journal:  Drugs       Date:  1995-08       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.